Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Elidel · 1 trial · 1 indication
F-IGA is defined as Facial Investigator's Global Assessment, which incorporates assessments of the severity of facial seborrheic dermatitis. Scoring is 0 to 3, 0 describing a better outcome with progressively worsening up to 3 representing a worse outcome (whole number only). 0 = Clear; 1 = Mild; 2 = Moderate and 3 = Severe. Scoring is based upon morphologic description of signs of erythema (0 =none, 1= faint, 2 =dull, 3 =deep/dark red) and scaling (0 = none, 1 = minute, powdery scale, 2 = thin flakes of scale, 3 = scales covering most of the involved areas).
| Arm | Type | Description |
|---|---|---|
| Elidel Cream (pimecrolimus) | EXPERIMENTAL | Elidel Cream to be applied twice daily for 4 weeks |
| Ketoconazole Cream (Nizoral) | ACTIVE_COMPARATOR | Ketoconazole Cream to be applied twice daily for 4 weeks |
| Name | Type | Description |
|---|---|---|
| Elidel | DRUG | - |
| Ketoconazole Cream | DRUG | - |
Inclusion Criteria: * Must be 18 or older and sign written informed consent. * Must be wiling and able to comply with protocol. * Must have active seborrheic dermatitis of the face. Exclusion Criteria: * No history of overt bacterial, viral or fungal infection of the head/neck. * No history or pr...
Elidel is a small molecule being studied for the treatment of Seborrheic Dermatitis, a common skin condition. It is currently in Phase 2 clinical development and is not yet approved for this indication. The drug is being investigated as a topical treatment to address the symptoms of this dermatological condition.
Elidel is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. Novartis is conducting clinical research to evaluate the safety and efficacy of Elidel for the treatment of Seborrheic Dermatitis.
Elidel is in Phase 2 clinical development for the treatment of Seborrheic Dermatitis. It is an investigational drug and has not received regulatory approval for this use. The Phase 2 trial has been completed, with results expected to inform further development decisions.
Elidel has one completed Phase 2 clinical trial registered under NCT00403559, titled "A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis." The trial enrolled 113 participants in the United States, was randomized and double-blind, and used an active control.
Elidel is also known as Pimecrolimus, as indicated in the clinical trial title. The drug is being investigated under the brand name Elidel for Seborrheic Dermatitis, and Pimecrolimus is the active pharmaceutical ingredient being studied in this Phase 2 trial.